Global Plasmid DNA Manufacturing Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Plasmid DNA manufacturing is a process of producing plasmid DNA that is directly used as a therapeutic agent such as in gene therapy or vaccine generation antigens. Factors such as the flourishing growth of the healthcare industry, the rising number of patients opting for gene therapy, and the increasing demand for plasmid DNA in various medical therapies are upsurging the market demand across the world.

According to Statista, in 2019, the global cancer gene therapy market was estimated to value around USD 560 million, which is anticipated to grow and is likely to reach USD 16,500 million by the year 2030. Therefore, the increasing demand for gene therapy is exhibiting a positive influence on the growth of the Plasmid DNA Manufacturing Market. In addition, a robust pipeline for gene therapies, as well as the increasing number of strategies by the key market players are offering various lucrative opportunities for market growth in the forecasting years. However, the imposition of a stringent regulatory framework and ethical challenges associated with gene therapy are hindering stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Plasmid DNA Manufacturing Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the space in terms of revenue, owing to the rising emphasis on the establishing Recombinant DNA Advisory Committee, along with the growing investment the R&D activities. Whereas, Asia Pacific is expected to grow significantly during the forecast period. Factors such as

rising inclination toward the development and marketing of stem cells, untapped opportunities, as well as growing incidences of target diseases are burgeoning the market growth in the forecasting years.

Major market players included in this report are:

Charles River Laboratories

VGXI, Inc.

Aldevron

Kaneka Corp.

Nature Technology

Cell and Gene Therapy Catapult

Eurofins Genomics

Lonza

Luminous BioSciences, LLC

Akron Biotech

Recent Developments in the Market:

in July 2021, Thermo Fisher announced the establishment of its current Good Manufacturing Practice (cGMP) facility in Carlsbad, California, with the objective of boosting its clinical and business capabilities for the synthesis of pDNA for cells and gene-based therapies.
In June 2021, Biotage announced the introduction of Biotage PhyPrep- a new automated solution for plasmid DNA purification. This new automated solution for plasmid DNA purification saves lab technicians' time by eradicating the requirement to perform repetitive, manual work and also helps in producing supercoiled, endotoxin-free, transfection-grade pDNA.
Global Plasmid DNA Manufacturing Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered Grade, Development, Application, Disease, Region

Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Grade:

R&D Grade

GMP Grade

By Development:

Pre-Clinical Therapeutics

Clinical Therapeutics

Marketed Therapeutics

By Application:

DNA Vaccines

Cell & Gene Therapy

Immunotherapy

Others

By Disease:

Infectious Disease

Cancer

Genetic Disorder

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World